Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.

Emerging nanoparticles for glioblastoma: Engineering precision across the blood-brain barrier

Glioblastoma (GBM) remains one of the most lethal brain malignancies, characterized by aggressive invasion, therapeutic resistance and poor prognosis. Conventional treatment approaches are limited by systemic toxicity, poor blood–brain barrier (BBB) penetration and lack of tumor specificity. Nanoparticle-based therapeutics offer a transformative paradigm redefining drug delivery, diagnostics and multimodal strategies in GBM. In this review, we critically explore a diverse variety of advanced nanocarrier platforms designed for anti-proliferative, radiosensitizing and immunomodulatory interventions. These systems enhance BBB penetration, tumor localization and enable co-delivery of chemotherapeutics, gene therapies and imaging agents with high precision. Innovative approaches show efficacy against glioma stem cells, modulate the tumor microenvironment and address resistance mechanisms. Integration with radiotherapy and immunotherapy yields synergistic tumor suppression and immune activation, advancing personalized nanomedicine. Despite these advancements, translational hurdles remain nanogenotoxicity, long-term biosafety, immune responses and regulatory barriers. This review emphasizes such challenges while identifying opportunities for strategic innovation in GBM nanotherapy. By uniquely bridging preclinical advances with emerging clinical perspectives, we highlight its distinct contribution within the field. By bridging nanotechnology, molecular oncology and bioengineering, we highlight how rational nanoparticle design can shift GBM management toward targeted, multimodal precision therapy, offering renewed hope against one of oncology’s most intractable diseases. Keywords: Glioblastoma, Nanoparticles, Blood-Brain Barrier, Nanotechnology, Nanomedicine, Nanotherapeutics.

BBB-Targeted Polymeric Nanocarriers for Paclitaxel Delivery in Glioblastoma Therapy: A Comprehensive Review on Polymeric Systems, Targeting Mechanisms, Clinical Challenges in Glioblastoma and Future Prospects

Glioblastoma remains one of the most lethal brain malignancies, characterized by aggressive proliferation and high recurrence rates despite multimodal treatment approaches. While paclitaxel demonstrates potent anticancer activity, its clinical utility in glioblastoma management is severely hampered by its inability to cross the bloodbrain barrier, coupled with poor aqueous solubility and P-glycoprotein-mediated efflux. Current standard care, based on surgical resection combined with radiotherapy and chemotherapy, yields disappointing median survival rates of only 12-15 months, underscoring the urgent need for innovative therapeutic strategies. Nanotechnologybased drug delivery systems have emerged as a promising approach to circumvent these limitations. Polymeric nanoparticles, including PLGA, PLA, PCL, and chitosan-based formulations, can effectively encapsulate paclitaxel while protecting it from efflux mechanisms and enhancing cellular uptake through receptor-mediated pathways. Surface functionalization strategies such as PEGylation, peptide conjugation, and targeting ligand attachment significantly improve blood-brain barrier penetration and tumor-specific accumulation. Despite promising preclinical results demonstrating substantial improvements in brain drug concentrations and tumor growth suppression, several obstacles persist in advancing these systems to clinical practice. These include manufacturing scalability, formulation stability, regulatory requirements, and standardization of quality control parameters. Furthermore, tumor heterogeneity and variable receptor expression patterns necessitate personalized therapeutic approaches. This review highlights recent progress in BBB-targeted paclitaxel nanoparticle systems, outlines key technological advances, addresses current limitations, and identifies future research priorities essential for successful clinical translation in glioblastoma therapy.

Cancer Nanomedicine: Advanced Nanocarrier Systems, Targeted Drug Delivery, Theranostics, and Emerging Strategies for Precision Oncology

Cancer remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in diagnosis and treatment. Conventional therapeutic approaches, including chemotherapy, radiotherapy, surgery, and immunotherapy, are often limited by poor tumor selectivity, systemic toxicity, multidrug resistance, and inadequate drug accumulation at the disease site. Nanomedicine has emerged as a transformative strategy in oncology, offering innovative solutions for targeted drug delivery, improved pharmacokinetics, enhanced therapeutic efficacy, and reduced off-target toxicity. Owing to their unique physicochemical properties, nanoparticles can be engineered to overcome biological barriers associated with tumor progression and facilitate precise delivery of therapeutic and diagnostic agents. This review comprehensively discusses the fundamental principles of cancer nanomedicine, including tumor biology, barriers to drug delivery, and critical design considerations for nanocarrier development. Various classes of nanomaterials, including polymeric nanoparticles, lipid-based systems, inorganic nanomaterials, and emerging biomimetic platforms, are examined with respect to their structural characteristics, therapeutic applications, and translational potential. Particular emphasis is placed on tumor-targeting strategies, encompassing passive, active, and microenvironment-responsive approaches, as well as on the development of smart stimuli-responsive nanocarriers capable of controlled, site-specific drug release. Furthermore, recent advances in nanotechnology-enabled chemotherapy, combination therapy, gene and RNA delivery, immuno-nanomedicine, and theranostic platforms are highlighted. The integration of diagnostic imaging and therapeutic functions within multifunctional nanocarriers has enabled real-time monitoring of treatment response and personalized cancer management. In addition, challenges associated with safety, toxicity, large-scale manufacturing, regulatory approval, and clinical translation are critically evaluated. Emerging innovations, including artificial intelligence-driven nanocarrier design, biomimetic nanomedicines, and precision oncology approaches, are also explored as future directions for the field.Overall, cancer nanomedicine has evolved from a simple drug-delivery concept into a multifunctional therapeutic platform integrating targeted therapy, molecular imaging, immunomodulation, gene therapy, and personalized medicine. Continued interdisciplinary collaboration and technological innovation are expected to accelerate the clinical translation of next-generation nanomedicines, ultimately improving treatment outcomes and advancing precision cancer care.

Exploring the landscape of targetable alterations in patients with glioblastoma.

The therapeutic landscape of targeted therapies in glioblastomas is summarized, spanning major target classes including receptor tyrosine kinases, intracellular signalling proteins, cell-cycle dysregulation and synthetic-lethal vulnerabilities and emerging strategies targeting genome integrity and telomeres, epigenetic modulators, and tumour-neural circuitry are examined.

Nanocarriers in Ovarian Cancer: Targeted Drug Delivery, Theranostics, and Immunomodulation

Modern Therapies: Nanotechnology Promises New Approaches for Rare Breast Cancer to Brain Metastases.

Brain metastasis originating from breast cancer is an uncommon but clinically significant complication that poses substantial therapeutic challenges and is associated with poor patient prognosis. Traditional treatment modalities-including surgical resection, whole-brain radiation therapy, stereotactic radiosurgery, and systemic chemotherapy-often fail to achieve satisfactory long-term control due to the protective nature of the blood-brain barrier (BBB), tumor heterogeneity, and the aggressive biology of metastatic lesions. This comprehensive review delves into recent advances in modern therapeutic approaches that aim to enhance the efficacy of conventional treatments for rare brain metastases from breast cancer (BC). We systematically evaluate emerging strategies such as advanced drug delivery technologies, including nanoparticles (NPs), polymeric NPs, and liposomal formulations, which are designed to overcome pharmacokinetic limitations and improve the penetration and retention of chemotherapeutic agents within the central nervous system (CNS). The review also explores the integration of immunotherapies, particularly immune checkpoint inhibitors and adoptive cell therapies-with traditional modalities to potentiate antitumor immune responses in the brain microenvironment. Moreover, we discuss the development and application of novel radiosensitizers and combination regimens aimed at overcoming the inherent and acquired radioresistance of metastatic tumors. The synthesis of current preclinical models and clinical trial data provides critical insights into the potential of these combined approaches to enhance patient survival and quality of life. Finally, we identify key challenges, including the need for personalized treatment protocols and the management of therapy-related toxicities, and propose future directions for research.